Medtronic urology approval
This article was originally published in The Gray Sheet
Executive Summary
Firm announces FDA approval of its Interstim II system July 5. The implantable device uses sacral nerve stimulation to treat chronic, intractable cases of overactive bladder and urinary retention. According to Medtronic, the next-generation device is nearly half the size and weight of its predecessor. In May, the firm announced plans to pursue a pivotal trial for Interstim within the next year to establish better clinical evidence for the device's use...
You may also be interested in...
Medtronic InterStim
Firm submits a PMA application for treatment of fecal incontinence with the neurostimulation implant, anticipating a U.S. launch in 2009, Medtronic announces Oct. 22. The device, which works by stimulating the sacral nerve, has been approved since 2006 for urinary incontinence (1"The Gray Sheet" July 10, 2006, In Brief)
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip